Pyxis Oncology Management
Management criteria checks 3/4
Pyxis Oncology's CEO is Tom Civik, appointed in Feb 2026, has a tenure of less than a year. directly owns 0.36% of the company’s shares, worth $339.48K. The average tenure of the management team and the board of directors is 1.1 years and 4.5 years respectively.
Key information
Tom Civik
Chief executive officer
US$189.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.4% |
| Management average tenure | 1.1yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)
Sep 12Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Jun 19
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Dec 07Moment Of Truth Approaches For Pyxis Oncology
Sep 13Pyxis Oncology: Promising Research Amid Cash Constraints
Jun 10Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13CEO
Tom Civik (55 yo)
Mr. Thomas Civik, also known as Tom, is Independent Chairman of the Board at ImCheck Therapeutics SAS since March 2023. He is Interim CEO & Director of Pyxis Oncology, Inc. from February 3, 2026. He was In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | less than a year | US$189.53k | 0.36% $ 339.5k | |
| Chief Accounting Officer | 4.6yrs | no data | no data | |
| Interim Chief Technology Officer | 4.2yrs | no data | no data | |
| Chief Scientific Officer | 3.9yrs | no data | no data | |
| Senior Vice President of Investor Relations & Capital Markets | less than a year | no data | no data | |
| Head of Human Resources | 1.2yrs | no data | no data | |
| Senior Vice President of Portfolio & Program Management | 4.2yrs | no data | no data | |
| Senior VP & Chief Business Officer | 1.8yrs | no data | no data | |
| Head of Global Regulatory Affairs | 1yr | no data | no data | |
| Head of Commercial Development | 1yr | no data | no data | |
| Head of Biometrics | 1yr | no data | no data | |
| Head of ADC Development & Clinical Strategy | 1yr | no data | no data |
Experienced Management: PYXS's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | 4.5yrs | US$189.53k | 0.36% $ 339.5k | |
| Independent Chairman | 6.8yrs | US$230.71k | 0.66% $ 631.9k | |
| Member of Clinical & Translational Medicine Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 4.5yrs | US$179.89k | 0.39% $ 369.3k | |
| Independent Director | 4.5yrs | US$193.21k | 0.40% $ 384.6k | |
| Independent Director | 2yrs | US$493.63k | 0% $ 0 | |
| Member of Clinical & Translational Medicine Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | 3.9yrs | no data | no data | |
| Chairperson of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data |
Experienced Board: PYXS's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 00:45 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pyxis Oncology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Bradley Canino | Guggenheim Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |